SantoSolve Overview

  • Founded
  • 1994
  • Status
  • Out of Business
  • Employees
  • 8
  • Latest Deal Type
  • Out of Business

SantoSolve General Information


Developer of analgesic products intended to mitigate the adverse effects and health risks associated with existing pain drugs. The company's products are based on non-radioactive strontium and focus on pain treatment and inflammatory lesions, enabling patients to avail of a pharmaceutical formulation for the treatment of local and neuropathic pain conditions.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Enebakkveien 117A
  • 0680 Oslo
  • Norway
+47 21 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

SantoSolve Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Out of Business 000.00 Completed Out of Business
6. Secondary Transaction - Private 000.00 Completed Clinical Trials - Phase 3
5. Secondary Transaction - Private 01-Jun-2012 000.00 Completed Clinical Trials - Phase 3
4. Later Stage VC (Series C) 26-Sep-2009 00.00 000.00 Completed Clinical Trials - Phase 3
3. Later Stage VC 28-Nov-2008 000 Completed Generating Revenue
2. Later Stage VC 07-Nov-2007 $7M $7M Completed Generating Revenue
1. Later Stage VC 01-Jan-2004 Completed Generating Revenue
To view SantoSolve’s complete valuation and funding history, request access »

SantoSolve Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial